Urticaria is not a sentence. The clinical cases



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Omalizumab - monoclonal therapeutic antibody to human IgE, is effectively used for the treatment of patients with chronic spontaneous urticaria (HSC), refractory to 4 times increased doses of antihistamines. The article describes two cases of effective treatment of patients (HSC) with omalizumab (Xolair® «Novartis Pharma» LLC) after a long period of unsuccessful therapy with H1-antihistamines, leukotriene receptor antagonists, and corticosteroids.

Full Text

Restricted Access

About the authors

I V Danilycheva

Institute of Immunology

Email: ivdanilycheva@mail.ru

A E Shulzhenko

Institute of Immunology

N G Bondarenko

Institute of Immunology

References

  1. Федеральные клинические рекомендации по диагностике и лечению крапивницы. Российская ассоциация аллергологов и клинических иммунологов. Росс. Аллергол. Журн. 2011, № 1, с. 38-46.
  2. Zuberbier Т., Aberer W., Asero R. EAACI/GA2LEN/EDF/ WAO urticaria guideline for the definition, classification, diagnosis, and management of urticaria:the 2013 revision and update. Allergy. 2014.
  3. Maurer M., Weller K., Bindslev-Jensen C. et al. Unmet clinical needsin chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011, v. 66, p. 317-330.
  4. Martin Metz, Tatevik Ohanyan, Martin K. Church et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science. 2014, v. 73, p. 57-62.
  5. Saini S., Rosen K.E., Hsieh H.J. et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J. Allergy Clin. Immunol. 2011, v. 128, p. 567-573.
  6. Maurer M., Rosen K.E., Hsieh H.J. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 2013, v. 368 (10), p. 924-935.
  7. NHS England. Specialised Services Circular. NICE Technology Appraisal 339: Omalizumab for previously treated chronic spontaneous urticaria. 10 August 2015.
  8. Daut V. et al. HNO 2012, v. 60 (5), p. 457-465.
  9. Xolair (omalizumab) 150 mg Solution for Injection Summary of product Characteristics. Novartis Pharmaceuticals UK Ltd. Updated 7th July 2015.
  10. Zuberbier T. et al. Allergy. 2014, v. 69 (7), p. 868-887.

Copyright © Pharmarus Print Media, 2016



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies